Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Precigen Announced Enrollment Completion For Dose Level 3 Of Lymphodepletion Cohort, Provides Pipeline Update At J.P. Morgan Health Conference
PRGN-3006 UltraCAR-T in Acute Myeloid Leukemia (AML)
Overview: PRGN-3006 is an investigational multigenic, autologous chimeric antigen receptor T cell (CAR-T) therapy engineered to simultaneously express a CAR
5 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Precigen Posts Additional Interim Data From Type 1 Diabetes Trial
Precigen Inc’s (NASDAQ:PGEN) subsidiary Precigen ActoBio has announced additional interim data from Phase 1b/2a study of AG019 ActoBiotics for recent-onset type 1 diabetes…
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 30)
Precigen Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q2, Precigen's (NASDAQ:PGEN) reported sales totaled $33.58 million. Despite a 11.39% increase in earnings, the company posted a loss of $15.67 million.
Precigen: Q2 Earnings Insights
Shares of Precigen (NASDAQ:PGEN) moved lower in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 61.54% year over year to ($0.10), which beat the estimate of ($0.12).